Neil Versel

The purchase of GeneDx from Opko Health will help Sema4 accelerate its push into whole-exome sequencing and grow in rare disease diagnostics.

The company, which launched at the CES trade show last week, is also developing a small device for rapid analysis of long-read whole-genome sequences.

The Israeli government-funded group of biotech, pharma, computational biology, and agriculture interests has developed software for predicting CRISPR guide RNA.

After getting called out by informaticians at AMIA, Cerner and Epic address perceived shortfalls in their technology as demand for clinical genomics grows.

The Unified Patient Network expects pharmaceutical companies to sponsor whole-genome sequencing for patients from health systems for research and clinical purposes.

The bioinformatics firm hopes its AI and "NASA-style" command center will make it easier to get cancer patients into NGS labs and improve trial matching.

GE recently inked deals with Sophia Genetics, the University of Cambridge, and Optellum to improve early diagnosis of cancer with genomics and AI.

With $8 million in new funding, the startup is expanding beyond its DTC roots by offering "legit science" to support its personalized health recommendations.

The Montreal startup wants its informatics technology to help make precision medicine ubiquitous on the front lines of treatment.

With the help of an internally self-developed analytics tool, University of Pennsylvania researchers run GWAS to uncover sex-specific genetic associations for COPD risk.